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Arenaviruses include several important human pathogens, and there are very limited options of preventive
or therapeutic interventions to combat these viruses. An off-label use of the purine nucleoside analogue
ribavirin (1--D-ribofuranosyl-1-H-1,2,4-triazole-3-carboxamide) is the only antiviral treatment currently
available for arenavirus infections. However, the ribavirin antiviral mechanism action against arenaviruses
remains unknown. Here we document that ribavirin is mutagenic for the prototypic arenavirus lymphocytic
choriomeningitis virus (LCMV) in cell culture. The mutagenic activity of ribavirin on LCMV was observed
under single- and multiple-passage regimes and could not be accounted for by a decrease of the intracellular
GTP pool promoted by ribavirin-mediated inhibition of inosine monophosphate dehydrogenase (IMPDH). Our
findings suggest that the antiviral activity of ribavirin on arenaviruses might be exerted, at least partially, by
lethal mutagenesis. Implications for antiarenavirus therapy are discussed.
Arenaviruses are a group of enveloped viruses with a biseg-
mented negative-strand RNA genome. Both the small (S) and
large (L) genome RNAs use an ambisense coding strategy to
direct the synthesis of two proteins; the S segment encodes the
virus nucleoprotein (NP) and glycoprotein (GPC), whereas the
L segment encodes the virus polymerase (L) and matrix (Z)
proteins. Arenaviruses cause persistent infection in rodents
with a worldwide distribution (11, 13, 72, 72a). Several arena-
viruses can infect humans, which may result in severe clinical
symptoms, including hemorrhagic fever (HF) disease in areas
of South America (Junin virus in Argentina, Machupo virus in
Bolivia, and Sabia virus in Brazil) and West Africa (Lassa and
Lujo viruses). HF arenaviruses are a great public health con-
cern in the regions where these viruses are endemic. In addi-
tion, arenaviruses also pose a biodefense threat, and six arena-
viruses are category A agents (12, 13, 27, 72, 72a). On the other
hand, the prototypic arenavirus lymphocytic choriomeningitis
virus (LCMV) provides investigators with a superb model sys-
tem for the investigation of virus-host interactions and associ-
ated disease (reviewed in references 72 and 72a). Moreover,
mounting evidence indicates that LCMV is a neglected human
pathogen of clinical significance (9, 31, 45, 73).
Public health concerns about arenavirus infections of hu-
mans are further exacerbated because of the lack of licensed
vaccines and current therapy being limited to an off-label use
of the purine nucleoside analogue ribavirin (1--D-ribofurano-
syl-1-H-1,2,4-triazole-3-carboxamide) (1, 13, 36, 55, 66, 68).
Ribavirin has been licensed for human use as an antiviral agent
for 4 decades (86, 89). It is administered either alone or in
combination with other antiviral agents, and it is currently
employed to treat chronic hepatitis C in combination with
pegylated alpha interferon (IFN-) and respiratory syncytial
virus infections in infants and is used off-label to treat some
other respiratory infections (21–23, 44, 66, 67). The antiviral
activity of ribavirin is mediated by several mechanisms, includ-
ing inhibition of the cellular inosine monophosphate dehydro-
genase (IMPDH) and viral mutagenesis (reviewed in reference
37). The mutagenic activity of ribavirin was discovered with
poliovirus (18) and then documented with several additional
RNA viruses (37). Ribavirin triphosphate (RTP) is a substrate
for the RNA-dependent RNA polymerases (RdRps) of some
RNA viruses, and the incorporation of RTP in place of ATP or
GTP results in mutagenic activity during viral RNA elongation
(3, 5, 7, 17, 18, 62, 87).
LCMV exhibits the high mutation rates and quasispecies
dynamics typical of RNA viruses, and this confers this patho-
gen great adaptability to different environments (26, 28, 85).
Because of the need to explore new strategies for the control of
arenavirus-associated disease, we took LCMV as a model
system to investigate lethal mutagenesis or virus extinction
through an increase in the mutation rate (for reviews, see
references 6, 24, 32, and 38). The analogue 5-fluorouracil (FU)
is an effective mutagenic agent for LCMV and can lead to viral
extinction through a decrease in the specific infectivity of the
mutagenized virus (39–41). Ribavirin has also been used to
extinguish RNA viruses by lethal mutagenesis (38). However,
in studies in which ribavirin was administered to arenavirus-
infected cells or animals, the drug acted as an inhibitor of viral
replication, but no mutagenic activity was reported (29, 43, 49,
51, 60, 81, 83, 88). In our previous studies on lethal mutagen-
esis, we documented a higher efficacy of a mutagen-inhibitor
combination treatment over administration of a mutagen alone
(74, 92). In an exploration of protocols to achieve extinction of
* Corresponding author. Mailing address: Centro de Biología Mo-
lecular Severo Ochoa (CSIC-UAM), Consejo Superior de Investiga-
ciones Científicas (CSIC), Campus de Cantoblanco, 28049 Madrid,
Spain. Phone: 34-911964540. Fax: 34-911964420. E-mail: edomingo
@cbm.uam.es.
 Published ahead of print on 11 May 2011.
7246
foot-and-mouth disease virus (FMDV) using ribavirin as a
mutagenic agent and guanidine hydrochloride as an inhibitor
of FMDV replication, we observed an advantage of a sequen-
tial inhibitor-mutagen treatment over the corresponding com-
bination treatment (77). The scope of the advantage of the
sequential treatment is currently under investigation. Since the
advantage of the sequential treatment was dependent on one
of the drugs being a mutagenic agent, we reexamined the
inhibitory and potential mutagenic activity of ribavirin on
LCMV. Here we provide evidence that besides its well-docu-
mented inhibitory activity on arenavirus multiplication, ribavi-
rin also exerts mutagenic activity when present at subinhibitory
concentrations (that is, concentrations that result in lower but
detectable progeny production) during virus replication in cul-
tured cells. The inhibitory and mutagenic activities of ribavirin
were largely reversed by supplying cells with excess guanosine,
suggesting that both activities may operate in competition with
intracellular GTP. However, the mutagenic activity of ribavirin
on LCMV cannot be attributed to a depletion of intracellular
GTP levels as a result of inhibition of IMPDH, because treat-
ment with mycophenolic acid (MPA), an inhibitor of IMPDH
(33), did not exert any detectable mutagenic activity on
LCMV. Our findings raise the possibility that lethal mutagen-
esis promoted by ribavirin-induced mutagenesis might contrib-
ute to the antiviral activity of ribavirin against LCMV and
arenaviruses in general.
MATERIALS AND METHODS
Cells, virus, and drugs. Lymphocytic choriomeningitis virus (LCMV) strain
Armstrong (Arm) 53b is a clone from LCMV Arm CA that was plaque purified
three times and passaged four times in BHK-21 cells. This virus was used for all
cell culture infections described in the present study. Procedures to grow
BHK-21 and Vero cells and to infect cells with LCMV have been previously
described (39–41, 64). Briefly, for single-step infections, BHK-21 cells were
infected with LCMV at a multiplicity of infection (MOI) of 10 PFU/cell in the
presence or absence of ribavirin, mycophenolic acid (MPA), or guanosine or
combinations of these drugs at the concentrations indicated for each experiment.
Progeny virus was collected at 48 h postinfection (p.i.) from the cell culture
medium. For serial passages, infections of BHK-21 cells were carried out at an
MOI of 0.01 PFU/cell in the presence or absence of drugs as indicated for each
experiment. In each passage, the cells were infected with the progeny virus from
the preceding infection and collected at 48 h postinfection. For LCMV infections
in the presence of ribavirin, BHK-21 cells were preincubated with the desired
amount of ribavirin (Sigma) (0, 10, 20, or 100 M) for 7 h, and the same ribavirin
concentration was maintained throughout the infection. The toxicity of ribavirin
for BHK-21 cells under the culture conditions used in the present study has been
previously reported (3, 77). BHK-21 cells maintained at least 90% viability after
48 h of treatment with 100 M ribavirin compared to control BHK-21 cells
maintained in parallel in the absence of the drug. For LCMV infections in the
presence of 0, 5, and 30 M MPA, no toxicity for the cells was detected (100%
survival after 48 h in 30 M MPA). Treatment of BHK-21 cells with guanosine
(100 M), which did not result in detectable toxicity for the cells, was carried out
as previously described (5). LCMV was titrated by plaque assay on Vero cell
monolayers (4). Mock-infected BHK-21 and Vero cells were maintained in
parallel, and the corresponding cell culture supernatants were titrated to control
possible viral contamination. No infectivity was detected in the mock-infected
cultures at any time.
RNA extraction, RT-PCR amplification, and LCMV RNA quantification.
RNA was extracted from the supernatants of LCMV-infected cultures using
Trizol (Invitrogen), following the manufacturer’s instructions. LCMV RNA was
amplified by reverse transcriptase PCR (RT-PCR) using RT transcriptor
(Roche) and Pfu DNA polymerase (Promega) and the following pair of primers,
primers L3654F (F stands for forward) (5-AGTTTAAGAACCCTTCCCGC-3;
residues 3654 to 4268) and L4260R (R stands for reverse) (5-CGAGACACCT
TGGGAGTTGTGC-3; residues 4239 to 4260). Nucleotide positions are given
in the viral (genomic) sense and refer to the consensus genomic sequence
determined previously for the L segment (GenBank accession number
AY847351-L) (39). To ensure that in the RT-PCR amplification, excess LCMV
RNA template was present for quasispecies analysis, 1:10 and 1:100 dilutions of
the initial template preparations were amplified in parallel. Only preparations
that yielded a positive amplification band at the two dilutions were subjected to
molecular cloning and sequencing of individual clones (5). The amplified cDNAs
were either purified with a Wizard PCR purification kit (Promega) or subjected
to agarose (Pronadisa) gel electrophoresis; the cDNA band was extracted from
the gel using a QIAEX II gel extraction kit (Qiagen). Purified DNA was se-
quenced by Macrogen, Inc., to obtain the consensus sequence of the correspond-
ing population.
Genomic large (L) RNA was quantified by Light Cycler DNA Master SYBR
green I kit (Roche), according to the manufacturer’s instructions. The poly-
merase-coding region was amplified with primers L4183F (5-ATCGAGGCCA
CACTGATCTT-3; residues 4183 to 4202) and L4260R (5-CGAGACACCTT
GGAGTTGTGC-3; residues 4239 to 4260). An LCMV RNA fragment
spanning nucleotides 3662 to 4268 was used as the standard. This was obtained
as a runoff transcript from a molecular DNA clone of the polymerase-coding
region in the genomic sense, cloned into pGEM-T Easy vector (Promega). The
denaturation curve of the amplified DNAs was determined to monitor the
specificity of the reaction. Negative controls (without template RNA) were run
in parallel with each amplification reaction mixture. Each value is the average of
at least three determinations. The specific infectivity of LCMV was calculated by
dividing the number of progeny infectivity (PFU) by the amount of LCMV RNA
in the same volume of culture medium.
Molecular cloning and calculation of mutant spectrum complexity. Molecular
clones were prepared from cDNA (the band corresponding to the RT-PCR
amplification obtained with undiluted template) using primers L3654F and
L4260R (described above in “RNA extraction, RT-PCR amplification, and
LCMV RNA quantification”). cDNA was ligated to the pGEM-T Easy vector
(Promega) and transformed into Escherichia coli DH5. cDNA from individual
positive E. coli colonies was amplified with Templiphi (GE Healthcare) and
sequenced (Macrogen, Inc.).
The average mutation frequency among components of the mutant spectrum
of an LCMV population was calculated by dividing the number of different
mutations found by the total number of nucleotides sequenced. The Shannon
entropy (S) (which measures the proportion of different sequences in the region
analyzed) was calculated using the formula S  [i (pi  ln pi)]/ln N where pi
is the proportion of each sequence in the mutant spectrum and N is the total
number of sequences compared (94). An S value of 0 means that all sequences
are identical, while a value of 1 means that the sequences are different from each
other. Statistical significance values were calculated using Prism software pro-
gram version 5.0 or higher. The mutation frequency calculated for LCMV pas-
saged in the absence of ribavirin was at least 2.8-fold larger than can be attrib-
uted to the error incorporation during the RT-PCR procedure used (82).
RESULTS
Assessment of the inhibitory and mutagenic activity of riba-
virin during LCMV replication in cultured cells. We first com-
pared the inhibitory effect of ribavirin on LCMV multiplication
in BHK-21 cells following infection at a low MOI and a high
MOI (Fig. 1). The concentrations of ribavirin that produced a
decrease of 99% in the yield of infectious progeny (99% in-
hibitory concentrations [IC99]) were 4.28 	 0.24 M for the
infections carried out with an MOI of 0.01 PFU/cell and
12.83 	 0.61 M for the infections carried out with an MOI of
10 PFU/cell. Thus, the inhibitory effect of ribavirin on LCMV
was more pronounced in infections carried out at a low MOI.
Ribavirin has been recognized as a mutagen for several
RNA viruses (reviewed in reference 37). To investigate
whether ribavirin could exert a dual inhibitory and mutagenic
activity during LCMV replication, single-step infections were
carried out at an MOI of 10 PFU/cell in the presence and
absence of 20 M or 100 M ribavirin. The progeny infectivity,
progeny RNA, mutant spectrum complexity, and types of mu-
tations in the progeny populations were analyzed. The results
(Table 1) confirm a strong inhibitory activity of ribavirin, with
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at least a 106-fold reduction of virus titer and 102-fold reduc-
tion of viral RNA levels in the presence of 100 M ribavirin. It
must be noted that the specific infectivity of progeny LCMV
decreased 28.5-fold in the infection carried out in the presence
of 20 M ribavirin and at least 2,170-fold in the presence of
100 M ribavirin (considering the limit of detection of infec-
tivity [Table 1]). The significant decrease of specific infectivity
may be relevant to the mechanism of inhibition of LCMV
replication by ribavirin (see Discussion). The mutation fre-
quency among components of the LCMV population passaged
in the presence of 20 M ribavirin was significantly higher
(2.3-fold; P  0.0385 by 
2 test) than in the population pas-
saged in the absence of ribavirin. In contrast, no increase in
mutation frequency was detected in the mutant spectrum of
LCMV replicated in the presence of 100 M ribavirin com-
pared to LCMV replicated in the absence of ribavirin. The
difference of population complexity was also reflected in
the Shannon entropy (Table 1). Furthermore, examination of
the mutation types shows that the infection in the presence of
20 M ribavirin, but not in the presence of 100 M ribavirin,
led to a specific increase of G3A and C3U transitions (P 
0.05 by 
2 test) (Table 1). G3A and C3U are the types of
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FIG. 1. Inhibition of LCMV replication by ribavirin. BHK-21 cells
were infected with LCMV Armstrong (Arm) 53b at an MOI of either
0.01 PFU/cell or 10 PFU/cell. Viral titers were determined at 48 h
postinfection (p.i.) in triplicate, and standard deviations (error bars)
are given. The horizontal and vertical lines indicate the viral titer and
ribavirin concentration that yield the IC99 values (concentration of
ribavirin that produces a 99% inhibition of LCMV infectious progeny
production), given in the text as the average of triplicate determina-
tions. The broken line indicates the limit of detection of LCMV infec-
tivity. Note the different scale of the abscissa in the two plots. Proce-
dures for LCMV infection in the presence or absence of ribavirin and
for the determination of infectivity by plaque assays are detailed in
Materials and Methods.
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mutations previously associated with ribavirin mutagenesis (3,
5, 18). In the population passaged in the absence of ribavirin,
A3G and U3C transitions were more frequent than G3A
and C3U transitions, and the same bias was present in the
progeny of the infection carried out in the presence of 100 M
ribavirin (Table 1). In all cases, transitions were 3- to 5-fold
more frequent than transversions. The results strongly suggest
that ribavirin can exert a dual mutagenic and inhibitory activity
on LCMV.
Effect of guanosine on the inhibitory and mutagenic activity
of ribavirin exerted on LCMV. In the cell, ribavirin is phos-
phorylated into ribavirin mono-, di-, and triphosphate (RMP,
RDP, and RTP, respectively) by cellular enzymes (91, 98).
RMP acts as a competitive inhibitor of inosine monophosphate
dehydrogenase (IMPDH) and reduces the intracellular con-
centration of GTP (33, 90, 91). RTP is used as a substrate by
the RNA-dependent RNA polymerases (RdRps) of picorna-
viruses in place of GTP or ATP during RNA elongation re-
sulting in mutagenesis of viral RNA (3, 18, 30, 37, 69, 87). The
addition of guanosine to the cell culture medium can restore
intracellular GTP levels despite the presence of RMP (5, 50,
54, 98). To study whether GTP levels were involved in the
inhibition and mutagenesis of LCMV by ribavirin, single-step
infections were carried out in the presence or absence of riba-
virin and in the presence of 100 M guanosine, a concentration
that compensates for the decrease of GTP produced by riba-
virin treatment of BHK-21 cells (5). The results (Fig. 2 and
Table 1) show that the presence of guanosine in the culture
medium greatly reduced the inhibition of infectious LCMV
progeny production by 100 M ribavirin (16.6-fold decrease of
infectious progeny production in the presence of guanosine
versus at least a 112,121-fold reduction in the absence of
guanosine [Table 1]). Guanosine also prevented the increase
of mutation frequency and Shannon entropy associated with
the presence of 20 M ribavirin and abolished the differences
in the frequency of transition types observed between the mu-
tant spectra of LCMV passaged in the presence and absence of
20 M ribavirin (Table 1). Thus, the inhibitory and mutagenic
activities of ribavirin exerted on LCMV during virus replica-
tion were largely overcome by the presence of guanosine in the
culture medium, suggesting that inhibition and mutagenesis of
LCMV by ribavirin were mediated or enhanced by low intra-
cellular GTP levels.
Effect of treatment with mycophenolic acid on LCMV mul-
tiplication in cultured cells. Low intracellular GTP caused by
ribavirin treatment may favor misincorporation of AMP (if
RTP is not a substrate for LCMV polymerase) or both AMP
and RMP (if RTP is a substrate for the polymerase) in place of
GMP. To quantitate the mutagenic activity evoked by low
intracellular GTP levels in the absence of ribavirin, we con-
ducted LCMV infections in the presence or absence of MPA,
an inhibitor of IMPDH that cannot be incorporated into nu-
cleic acids (33). We conducted single-step LCMV infections
(MOI of 10 PFU/cell) in the presence or absence of 5 and 30
M MPA, as 30 M MPA results in a decrease of intracellular
GTP levels at least equal to the decrease produced by 500 M
ribavirin (5). The infections were done in the presence or
absence of 100 M guanosine. The results (Table 2) show that
MPA reduced LCMV infectious progeny production by 2.1- to
2.3-fold, an inhibition which is at least 48,000-fold lower than
the inhibition produced by ribavirin (compare Tables 1 and 2).
Guanosine totally compensated for the inhibition exerted by
MPA on LCMV progeny production (Table 2). The presence
of MPA did not lead to any increase in mutant spectrum
complexity, a result which contrasts with that obtained with 20
M ribavirin (Tables 1 and 2). In fact, the mutation frequency
and Shannon entropy of the LCMV that replicated in the
presence of 30 M MPA decreased 4.3- and 3.6-fold, respec-
tively, relative to the populations replicated in the absence of
MPA (Table 2). Thus, in contrast to ribavirin, MPA is not
mutagenic for LCMV. The decrease of mutant spectrum com-
plexity in the presence of MPA was associated mainly with a
lower frequency of A3G and U3 C transitions, the transition
types that LCMV tends to produce during replication. This
lower frequency is expected if this mutational tendency is fa-
FIG. 2. LCMV progeny production in the presence or absence of
ribavirin (R) and guanosine (GU). BHK-21 cells were infected with
LCMV Arm 53b at an MOI of 10 PFU/cell either in the absence of
drugs or in the presence of 100 M guanosine (GU) or 20 M or 100
M ribavirin (R20 and R100, respectively) (R, no ribavirin), as
indicated for each column. LCMV infectivity (top panel) and number
of LCMV RNA molecules measured by quantitative RT-PCR (bottom
panel) were determined in the cell culture supernatant at 48 h p.i.
Background values (PFU/ml and RNA/ml measured at time zero) have
been subtracted from each titer and number of RNA molecules, re-
spectively. The broken lines indicate the limit of detection for LCMV
infectivity and the number of RNA molecules. Values are means of
triplicate determinations, and standard deviations are given. Proce-
dures for infections, titration by plaque assay and LCMV RNA quan-
tification are described in Materials and Methods.
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vored by high intracellular GTP concentrations during LCMV
replication. Surprisingly, the amount of LCMV progeny RNA
decreased significantly in the virus produced in the presence of
MPA (P  0.05 by Student’s t test) (Table 2). As a conse-
quence, the specific infectivity of the LCMV produced in these
infections was 1.2- to 3.2-fold higher than that of the popula-
tion generated in the absence of drugs. Since mutagenesis of
RNA viruses is associated with decreases in specific infectivity
(2, 3, 34, 35, 39, 40, 76, 77), the increase in specific infectivity
that the virus undergoes in the presence of MPA and guano-
sine reinforces the conclusion of the absence of mutagenic
activity of MPA on LCMV. How alterations of intracellular
GTP levels can modify the specific infectivity of LCMV is
unknown (see Discussion). Thus, the mutagenic activity of
ribavirin cannot be attributed to the inhibition of IMPDH
exerted by RMP.
Assessment of ribavirin mutagenic activity and its preven-
tion by guanosine during serial LCMV infections in cultured
cells. The mutagenic activity of ribavirin on LCMV and its
compensation by guanosine (Fig. 2 and Table 1) were studied
in single-step infections carried out at a high MOI. The IC99
for ribavirin was 3-fold higher in the infections carried out at
an MOI of 10 PFU/cell than at 0.01 PFU/cell (Fig. 1). Infection
at a high MOI promotes accumulation of defective interfering
(DI) particles of LCMV (80, 95, 96), whereas infection at a low
MOI acts as a filter to eliminate DI particles whose replication
is dependent on standard, infectious LCMV. Previous studies
showed that a subset of defective but RNA replication-com-
petent LCMVs termed defectors could interfere with replica-
tion of standard LCMV and contribute to virus extinction (40,
42, 63). Since the proportion of defector LCMV genomes
increases with moderate intensities of mutagenesis (40), it was
important to ascertain that the mutagenic activity of ribavirin
observed during LCMV infection at a high MOI was not de-
pendent on DI particles and defector genomes. To achieve this
aim, we conducted parallel infections of BHK-21 cells at a low
(0.01 PFU/cell) and high (10 PFU/cell) MOI in the presence of
increasing concentrations of ribavirin (Fig. 3). Quantification
of infectivity and viral RNA after the first passage shows that
the inhibition of infectious progeny production by ribavirin
measured at 24 h and 48 h postinfection (p.i.) was 100- to
300-fold higher at a low MOI than at a high MOI (Fig. 3A and
B). In contrast, the decrease in viral RNA progeny production
by ribavirin was less pronounced at 48 h p.i. and almost absent
at 24 h p.i. at a low MOI (Fig. 3C and D).
The different effects of ribavirin on the yield of infectious
units and viral genomes resulted in a significant decrease of
specific infectivity due to ribavirin activity at an MOI of 0.01
PFU/cell at high concentrations of ribavirin (100 M), not at
low concentrations of ribavirin (5 and 20 M) (Fig. 3E). The
decrease in specific infectivity in the infection carried out in the
presence of 100 M ribavirin was diminished at a high MOI
(Fig. 3F). The results with an MOI of 10 PFU/cell are in
agreement with those reported in the previous series of inde-
pendent infections described in Table 1.
A total of nine passages were performed at a low MOI in the
presence of 10 M ribavirin to ensure continued virus infec-
tivity (absence of extinction) over nine passages. Evolution of
the infectivity values in the presence or absence of ribavirin
and guanosine in the course of the nine passages indicated an
inhibitory activity of ribavirin that decreased with passage
number and that was largely compensated for by the presence
of guanosine at all passages (Fig. 4 and Table 3). The yields of
infectivity and viral RNA at passage 1 were significantly re-
duced by 10 M ribavirin, resulting in a 15-fold increase in
specific infectivity. At passage 9, the inhibition by ribavirin
diminished and no difference in specific infectivity was de-
tected (Fig. 4 and Table 3). The mutation frequency and Shan-
non entropy at passage 9 were significantly higher in the virus
passaged in the presence of ribavirin than in the virus passaged
in the absence of ribavirin (P  0.005 by 
2 test), and the
increase was associated with G3A and C3U transitions, the
transition types expected from ribavirin mutagenesis. Guano-
sine compensated for the decrease of infectious progeny pro-
TABLE 2. Quasispecies analysis of LCMV populations produced in the presence or absence of mycophenolic acid and guanosinea
Mycophenolic
acid concn
(M)
Guanosine
concn
(M)
Progeny
infectivity
(PFU/ml)b
Progeny RNA
(mol/ml)c
Specific
infectivity
(PFU/mol
of RNA)d
Mutation
frequencye
Shannon
entropyf
No. of
nucleotides
sequencedg
Mutation types
Transition Transversionh
A3G G3A U3C C3U C3A A3C A3U
0 0 (1.9 	 0.5)  105 (1.0 	 0.01)  1010 1.9  105 4.8  104 0.29 34,720 10 1 4 0 2 0 1
100 (1.7 	 0.5)  105 (1.5 	 0.1)  1010 1.1  105 6.1  104 0.30 44,240 11 1 11 0 3 0 1
5 0 (8.1 	 3.6)  104 ND ND ND ND ND ND ND ND ND ND ND ND
100 (2.4 	 0.2)  105 ND ND ND ND ND ND ND ND ND ND ND ND
30 0 (9.0 	 2.0)  104 (3.7 	 0.3)  109 2.4  105 1.1  104 0.08 53,200 1 2 0 2 0 1 1
100 (5.5 	 1.2)  105 (1.5 	 0.0)  1010 3.6  105 1.9  104 0.12 53,200 3 3 1 0 0 1 0
a BHK-21 cell monolayers were infected at an MOI of 10 PFU/cell, and the infection was allowed to proceed in the presence of 0, 5 or 30 M mycophenolic acid
(MPA) and 0 or 100 M guanosine, as detailed in Materials and Methods. ND, not determined.
b Titer (see Materials and Methods) of LCMV populations obtained at 48 hpi. The corresponding background (time zero; after washing the monolayers) for each
infection has been subtracted from the remaining collected times.
c RNA quantification (described in Materials and Methods) of LCMV populations obtained at 48 hpi. The corresponding background (time zero; after washing the
monolayers) for each infection has been subtracted from the values obtained at subsequent times.
d Ratio between virus titer and number of viral RNA molecules per ml of LCMV population obtained at 48 hpi.
e Average number of mutations per nucleotide relative to the corresponding consensus sequence.
f Shannon entropy (S) is a measure of the number of different molecules in the mutant spectrum of the quasispecies. It is calculated by the formula S  i (pi 
ln pi)/ln N, in which pi is the frequency of each sequence in the quasispecies and N is the total number of sequences compared.
g Residues 3654 to 4260 (560 nucleotides) from the L gene were sequenced.
h Omitted transversions are not represented in the sequences analyzed.
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duction and progeny RNA levels associated with the presence
of ribavirin but compensated only partially for the increase of
mutant spectrum complexity evoked by ribavirin (Table 3).
Thus, several passage regimes indicate that ribavirin displays a
dual inhibitory and mutagenic activity for LCMV during virus
replication in cell culture, and both activities can be either
totally or partially prevented by the presence of guanosine in
the culture medium. The mutagenic activity of ribavirin on
LCMV cannot be explained as a result of the inhibition of
IMPDH by RMP.
DISCUSSION
The results described in the present study establish ribavirin
as a mutagenic agent for LCMV replicating in cell culture. It
remains to be determined whether this mutagenic activity of
ribavirin can also be observed in LCMV-infected mice and
whether these findings could be extended to other arenavi-
ruses. Ribavirin has been shown to be mutagenic for several
RNA viruses (3, 16, 17, 38, 54, 84, 87). However, for some
other RNA viruses tested, ribavirin did not exhibit noticeable
mutagenic activity (57, 59). Ribavirin is currently the only drug
therapy recommended to treat arenavirus infections, but its
mechanism of action has not been entirely elucidated. There is,
however, evidence indicating that ribavirin likely targets dif-
ferent steps of the arenavirus life cycle (58, 75).
We have now provided evidence that at subinhibitory con-
centrations, ribavirin exerts a mutagenic activity on LCMV.
One could envision at least two distinct mechanisms by which
ribavirin could exert a mutagenic activity on LCMV. (i) RMP
could mediate the inhibition of IMPDH, which could result in
depletion of intracellular GTP (33, 91), which would facilitate
incorporation of ATP instead of GTP opposite C in the tem-
plate (53, 65). (ii) RTP might be used as a substrate by the
arenavirus polymerase and be incorporated instead of ATP or
FIG. 3. Inhibition of LCMV progeny production by ribavirin. BHK-21 cells were infected with LCMV Arm 53b at an MOI of either 0.01
PFU/cell (left panels) or 10 PFU/cell (right panels) in the presence of the indicated concentrations of ribavirin (R) (0 to 100 M). The broken
lines indicate the limit of detection of LCMV infectivity and number of RNA molecules. Viral titers obtained in the presence of 100 M ribavirin
at an MOI of 0.01 PFU/cell and at 48 h at an MOI of 10 PFU/cell were below the limit of detection (indicated by a short black bar next to the
abscissa). Background values (PFU/ml and RNA/ml measured at time zero) have been subtracted from each titer and number of RNA molecules,
respectively. (A to F) Virus titers (A and B) and number of LCMV RNA molecules measured by quantitative RT-PCR (C and D) in the
supernatants of the infected cultures at 24 and 48 h postinfection were used to calculate the corresponding specific infectivities (E and F). The
asterisks in parentheses indicate that a specific infectivity was calculated assuming 1 PFU/ml, since the virus titer was below the limit of detection.
Procedures for infections, titration by plaque assay, and LCMV RNA quantification are described in Materials and Methods.
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GTP during arenavirus RNA synthesis. The subsequent am-
biguous reading within the template RNA of reading ribavirin
as G or A would result in increased numbers of mutations
during virus RNA replication as reported for picornaviruses (3,
17, 18, 87). These two mechanisms are not mutually exclusive,
and both could contribute to the mutagenic activity of ribavi-
rin. Our finding that MPA at concentrations in excess of those
required to produce the same depletion of GTP levels as found
with 100 M ribavirin in BHK-21 cells (5) did not display any
detectable mutagenic activity for LCMV (Table 2) supports
the conclusion that RMP-mediated inhibition of IMPDH can-
not account for the mutagenic activity of ribavirin on LCMV.
Guanosine largely reversed the inhibition of LCMV progeny
production exerted by either MPA or ribavirin (Fig. 2 and 4
and Tables 1 and 3). Interestingly, the ribavirin-induced in-
crease in mutation frequency and Shannon entropy observed in
infections done at a high, but not at a low, MOI were pre-
vented by the guanosine treatment (Tables 1 and 3). At the
concentration used, guanosine restores normal intracellular
GTP levels in BHK-21 cells (5), suggesting that the inhibitory
activity of ribavirin on LCMV is likely associated with de-
creased GTP levels caused by RMP-mediated inhibition of
IMPDH, whereas the mutagenic activity of ribavirin likely re-
flects its incorporation by the arenavirus polymerase into nas-
cent RNA molecules during virus replication. A direct dem-
onstration of a competition between RTP and GTP or ATP
during LCMV RNA synthesis will require in vitro assays to
assess the incorporation of RTP by the LCMV RdRp and the
isolation and mapping of ribavirin resistance mutations in
LCMV. It is worth noting that the observed decrease in riba-
virin-mediated inhibition of LCMV replication during serial
passages in the presence of 10 M ribavirin suggests the pos-
sible selection of an LCMV population with decreased sensi-
tivity to ribavirin, whose mutant spectrum tends to become
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FIG. 4. Infectious progeny production during serial passages of
LCMV in the presence of ribavirin and guanosine. BHK-21 cells were
infected with LCMV Arm 53b at an MOI of 0.01 PFU/cell either in the
presence or absence of 10 M ribavirin (R) or 100 M guanosine
(GU), or both, as indicated. The progeny virus was used to infect a
fresh BHK-21 cell monolayer under the same conditions, and infection
was repeated for a total of nine passages. Virus titers were determined
in triplicate in the supernatant of the infected cultures at 48 h p.i. The
broken line indicates the limit of detection of LCMV infectivity. Pro-
cedures for infections in the presence or absence of drugs and titration
by plaque assay are described in Materials and Methods.
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enriched in transition mutations (Fig. 4 and Table 3). This is a
subject currently under investigation in our laboratory.
Our results raise the question of whether the inhibitory and
mutagenic activities of ribavirin on LCMV are independent or
related. It is plausible that the strong inhibition of LCMV
production at high ribavirin concentrations was due to lethal
mutagenesis. Evidence against this possibility is the fact that
viral populations grown in the presence or absence of a high
concentration (100 M) of ribavirin exhibited similar mutation
frequencies and Shannon entropies (Table 1). A counterargu-
ment, however, is that highly mutated genomes do not survive
to be analyzed, and therefore, the genomes subjected to anal-
ysis were mainly genomes that underwent none, or minimal,
replication. It should be noted that LCMV progeny produced
in the presence of 100 M ribavirin displayed a severe reduc-
tion in specific infectivity (Fig. 3E and F), a hallmark of the
transition of viruses into error catastrophe (34, 40).
The findings presented here open the possibility that the
antiarenavirus activity of ribavirin might be exerted at least in
part through its mutagenic activity. There is evidence that
in whole organisms, ribavirin accumulates in blood rather than
in organs (15, 25, 47). Therefore, it is likely that in tissues
where LCMV replicates ribavirin, it is present at subinhibitory,
rather than inhibitory, concentrations. Notably, the mutagenic
activity of ribavirin could be observed at subinhibitory concen-
trations of ribavirin. Nevertheless, it may be difficult to asso-
ciate a therapeutic activity of ribavirin with mutagenesis during
treatment of human arenavirus infections, as exemplified by
the conflicting evidence in the case of ribavirin treatment of
hepatitis C virus (HCV) infections (8, 14, 20, 61, 78), despite
evidence of mutagenesis in HCV replicon systems (16, 48, 79,
97). The role of mutagenesis versus inhibition in the anti-
LCMV activity of ribavirin remains an open issue.
Whether an antiviral drug acts mainly as an inhibitor of virus
multiplication or as a mutagen is highly relevant for the design
of the optimal treatment protocols. Combination therapy is
generally accepted as a necessity to prevent or delay selection
of inhibitor-resistant viral mutants (10, 19, 46, 52, 56, 70, 71,
93). However, when a mutagenic agent is one of the compo-
nents of drug therapy, the sequential administration of giving
the inhibitor first and then the mutagenic agent can be more
effective than the corresponding combination treatment (77).
Therefore, the use of ribavirin in combination therapy with
novel antiarenavirus drugs yet to be developed would benefit
from determining the contribution of ribavirin-mediated mu-
tagenic effects to its overall antiarenavirus activity. Certainly,
the demonstration of viral mutagenesis by ribavirin in arena-
virus-infected individuals would not exclude a beneficial effect
of ribavirin by any of the alternative antiviral mechanisms
displayed by this nucleoside analogue (38, 58, 75, 90).
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